News

Philips Signs Health Care Sector Pledge to Reduce Emissions as part of Department of Health and Human Services, White House Initiative

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the company has joined…

2 years ago

Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5, 2022, at 11:59 p.m. ET

Key Proposal #2 has received significant support, but additional votes are needed for approval Leading Independent Proxy Advisory Firms, ISS…

2 years ago

Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors

BOSTON and LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a…

2 years ago

Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting, Acute Treatment for Type 2 Diabetes

Biomea to present two oral abstracts across multiple animal models highlighting the ability of BMF-219, a covalent menin inhibitor, to…

2 years ago

GeneType Risk Assessment Test onboarding in 16 clinics

MELBOURNE, Australia, July 01, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader…

2 years ago

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HOUSTON, July 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for…

2 years ago

Results of Annual General Meeting

DUBLIN, Ireland, and Boston MA, July 1, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing…

2 years ago

BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat)

—Analysis from APeX-S showed 98 percent attack-free days during treatment with ORLADEYO after switching from an injectable therapy—RESEARCH TRIANGLE PARK,…

2 years ago

FibroGen to Participate at William Blair Biotech Focus Conference 2022

SAN FRANCISCO, July 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer,…

2 years ago

New Data Reinforce Efficacy of the UroLift® System for the Treatment of Enlarged Prostate

Presentations at the 37th Annual European Association of Urology Congress to Demonstrate Measurable and Sustained Improvement of BPH Symptoms and…

2 years ago